Posted by Michael Wonder on 11 Nov 2020
CMS takes steps to ensure Medicare beneficiaries have wide access to COVID-19 antibody treatment
10 November 2020 - Coverage available at no cost to beneficiaries across variety of settings in health care system.
The Centers for Medicare & Medicaid Services announced that starting today, Medicare beneficiaries can receive coverage of monoclonal antibodies to treat coronavirus disease 2019 (COVID-19) with no cost-sharing during the public health emergency.
CMS’ coverage of monoclonal antibody infusions applies to bamlanivimab, which received an emergency use authorisation from the U.S. FDA yesterday.
